TS03 Inc Trust Units TSTIF

TOS Recap

[GoPats1]

TSO3 gave an incredibly upbeat outlook on its business during the quarterly conference call today. Highlights included: 
1) In the US, sterilizers are running 8-9 cycles/day. Management had been assuming 3 cycles/ day which equated to $25,000/year per sterilizer in consumables revenue. This new number would equate to $75,000/year per sterilizer!
2) Strategic hospital installs are pushing OEM equipment manufacturers to provide sterilization validation. They would rather use equipment that can be sterilized by a VP4 than disinfected.
3) More strategic hospital installs are currently being negotiated and almost complete.
4) The European launch of the VP4 has already begun with installs having taken place and many in delivery.
5) TSO3 has completed the FDA filing for sterilization of duodenoscopes. They have decided to partner with a well known OEM to joint file. They believe this will enhance their claims and speed up FDA approval. This will be a 2017 event and will be a complete game changer as over 500,000 procedures are done each year using duodenoscopes. TSO3 will then be the only company to have claims that terminally sterilize this equipment.
6) Getinge, their channel partner, thinks that over time the VP4 will displace steam sterilization. This is a huge market.